The first two weeks of 2021 have been quiet on the US FDA drug approval front, but the annual (albeit virtual) J.P. Morgan conference once again ensured a steady flow of sponsor news.
The approvals concentrated in oncology, including new breakthrough therapy designated-indications for Enhertu and Xalkori, while the submissions ranged from primary...





